Angiotensin I-converting enzyme inhibitors block protein kinase Cε by activating bradykinin B1 receptors in human endothelial cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 316, Issue 3, 2006, Pages 1153-1158

  Stanisavljevic, Sinisa ^a   Ignjatovic, Tatjana ^a   Deddish, Peter A ^a   Brovkovych, Viktor ^a   Zhang, Kai ^a   Erdös, Ervin G ^a,b   Skidgel, Randal A ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,3 BIS(2 AMINOETHYL) 1 HYDROXY 2 OXOTRIAZENE; AMINOPEPTIDASE; BRADYKININ B1 RECEPTOR; BRADYKININ B1 RECEPTOR AGONIST; BRADYKININ[1 LYSINE 10 DEARGININE]; BRADYKININ[1-8]; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOENZYME; LEUCYLLEUCYLPROLYLHISTIDYLGLUTAMYLALANYLTRYPTOPHANYLHISTIDYLPHENYLALANYL ALANYLARGININE; N [3 (AMINOMETHYL)BENZYL]ACETAMIDINE; N(G) NITROARGININE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE INHIBITOR; PROTEIN KINASE C EPSILON; PROTEIN KINASE C INHIBITOR; QUINAPRILAT; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; ZINC ION;

ARTICLE; BINDING SITE; CONTROLLED STUDY; DISEASE COURSE; DRUG BINDING SITE; DRUG EFFECT; DRUG RECEPTOR BINDING; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; HEART DISEASE; HEART INFARCTION; HUMAN; HUMAN CELL; IC 50; INHIBITION KINETICS; MICROVASCULATURE; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BLOCKING; UPREGULATION; VASCULAR ENDOTHELIUM;

AMINO ACID SEQUENCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CELLS, CULTURED; ENDOTHELIAL CELLS; HUMANS; KALLIDIN; MOLECULAR SEQUENCE DATA; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE; PROTEIN KINASE C-EPSILON; RECEPTOR, BRADYKININ B1;

EID: 33644779818     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.093849     Document Type: Article

References (37)

1. Bhoola KD, Figueroa CD, and Worthy K (1992) Bioregulation of kinins: kallikreins, kininogens and kininases. Pharmacol Rev 44:1-80.
2. Burch RM and Kyle DJ (1992) Recent developments in the understanding of bradykinin receptors. Life Sci 50:829-838.
3. Castrillo A, Pennington DJ, Otto F, Parker PJ, Owen MJ, and Bosca L (2001) Protein kinase C epsilon is required for macrophage activation and defense against bacterial infection. J Exp Med 194:1231-1242.
4. Christopher J and Jaffa AA (2002) Diabetes modulates the expression of glomerular kinin receptors. Int Immunopharmacol 2:1771-1779.
5. Corvol P, Eyries M, and Soubrier F (2004) Peptidyl-dipeptidase A/angiotensin I-converting enzyme, in Handbook of Proteolytic Enzymes (Barrett AJ, Rawlings ND, and Woessner JF eds) 2nd ed, pp 332-346, Academic Press, San Diego, CA.
6. Erdös EG, Deddish PA, and Marcic BM (1999) Potentiation of bradykinin actions by ACE inhibitors. Trends Endocrinol Metab 10:223-229.
7. Erdös EG, Renfrew AG, Sloane EM, and Wohler JR (1963) Enzymatic studies on bradykinin and similar peptides, in Structure and Function of Biologically Active Peptides: Bradykinin, Kallidin and Congeners (Erdös EG ed) pp 222-234, The New York Academy of Sciences, New York.
8. Erdös EG and Skidgel RA (1997) Metabolism of bradykinin by peptidases in health and disease, in The Kinin System (Farmer SG ed) pp 111-141, Academic Press, London, UK.
9. Gavras H, Brunner HR, Laragh JH, Sealey JE, Gavras I, and Vukovich RA (1974) An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N Engl J Med 291:817-821.
10. Gavras I and Gavras H (2001) The role of ACE inhibition in heart failure, in ACE Inhibitors (D'Orleans-Juste P and Plante GE eds) pp 71-79, Birkhauser-Verlag, Switzerland.
11. Goldspink PH, Montgomery DE, Walker LA, Urboniene D, McKinney RD, Geenen DL, Solaro RJ, and Buttrick PM (2004) Protein kinase C epsilon overexpression alters myofilament properties and composition during the progression of heart failure. Circ Res 95:424-432.
12. Goldstein A, Aronow L, and Kalman SM (1974) Principles of Drug Action: The Basis of Pharmacology, 2nd ed, pp 99-100, John Wiley & Sons, New York.
13. Hess JF, Derrick AW, MacNeil T, and Borkowski JA (1996) The agonist selectivity of a mouse B1 bradykinin receptor differs from human and rabbit B1 receptors. Immunopharmacology 33:1-8.
14. 1 receptors stimulate nitric oxide production in endothelial cells: signaling pathways activated by angiotensin I-converting enzyme inhibitors and peptide ligands. Mol Pharmacol 66:1310-1316.
15. Ignjatovic T, Tan F, Brovkovych V, Skidgel RA, and Erdös EG (2002) Novel mode of action of angiotensin I converting enzyme inhibitors: direct activation of bradykinin B1 receptor. J Biol Chem 277:16847-16852.
16. Kintsurashvili E, Duka A, Ignjacev I, Pattakos G, Gavras I, and Gavras H (2005) Age-related changes of bradykinin B1 and B2 receptors in rat heart. Am J Physiol 289:H202-H205.
17. Li RCX, Ping P, Zhang J, Wead WB, Cao X, Gao J, Zheng Y, Huang S, Han J, and Bolli R (2000) PKCepsilon modulates NF-kappa B and AP-1 via mitogen-activated protein kinases in adult rabbit cardiomyocytes. Am J Physiol 279:H1679-H1689.
18. Limbird LE (2004) The receptor concept: a continuing evolution. Mol Interv 4:326-336.
19. Mancini GBJ, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Luscher TF, Klibaner MI, et al. (1996) Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on reversing endothelial dysfunction) study. Circulation 94:258-265.
20. Marceau F and Regoli D (2004) Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov 3:845-852.
21. 2 receptor. Hypertension 33:835-843.
22. Matsumori A (2004) The role of NF-kappaB in the pathogenesis of heart failure and endotoxemia. Drugs Fut 29:733-739.
23. McLean PG, Perretti M, and Ahluwalia A (2000) Kinin B1 receptors and the cardiovascular system: regulation of expression and function. Cardiovasc Res 48:194-210.
24. Meneton P, Bloch-Faure M, Hagege AA, Ruetten H, Huang W, Bergaya S, Ceiler D, Gehring D, Martins I, Salmon G, et al. (2001) Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice. Proc Natl Acad Sci USA 98:2634-2639.
25. Minshall RD, Tan F, Nakamura F, Rabito SF, Becker RP, Marcic B, and Erdös EG (1997) Potentiation of the actions of bradykinin by angiotensin I converting enzyme (ACE) inhibitors: the role of expressed human bradykinin B2 receptors and ACE in CHO cells. Circ Res 81:848-856.
26. Ni C-W, Wang DL, Lien S-C, Cheng J-J, Chao Y-J, and Hsieh H-J (2003) Activation of PKC-ε; and ERK1/2 participates in shear-induced endothelial MCP-1 expression that is repressed by nitric oxide. J Cell Physiol 195:428-434.
27. Raidoo DM, Ramsaroop R, Naidoo S, Muller-Esterl W, and Bhoola KD (1997) Kinin receptors in human vascular tissue: their role in atheromatous disease. Immunopharmacology 36:153-160.
28. Schmaier AH (2003) The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction. Am J Physiol 285:R1-R13.
29. Schneck KA, Hess JF, Stonesifer GY, and Ransom RW (1994) Bradykinin B1 receptors in rabbit aorta smooth muscle cells in culture. Eur J Pharmacol 266:277-282.
30. Simonis G, Braun MU, Kirrstetter M, Schon SP, and Strasser RH (2003) Mechanisms of myocardial remodeling: ramiprilat blocks the expressional upregulation of protein kinase C-epsilon in the surviving myocardium early after infarction. J Cardiovasc Pharmacol 41:780-787.
31. Stawowy P, Margeta C, Blaschke F, Lindschau C, Spencer-Hansch C, Leitges M, Biagini G, Fleck E, and Graf K (2005) Protein kinase C epsilon mediates angiotensin II-induced activation of beta(1)-integrins in cardiac fibroblasts. Cardiovasc Res 67:50-59.
32. Takeishi Y, Ping P, Bolli R, Kirkpatrick DL, Hoit BD, and Walsh RA (2000) Transgenic overexpression of constitutively active protein kinase C epsilon causes concentric cardiac hypertrophy. Circ Res 86:1218-1223.
33. Ueno A, Dekura E, Kosugi Y, Yoshimura M, Naraba H, Kojima F, and Oh-ishi S (2002) Effects of dexamethasone and protein kinase C inhibitors on the induction of bradykinin B1 mRNA and the bradykinin B1 receptor-mediated contractile response in isolated rat ileum. Biochem Pharmacol 63:2043-2053.
34. Wang J, Liu X, Sentex E, Takeda N, and Dhalla NS (2003) Increased expression of protein kinase C isoforms in heart failure due to myocardial infarction. Am J Physiol 284:H2277-H2287.
35. Webster ME and Pierce JV (1963) The nature of the kallidins released from human plasma by kallikreins and other enzymes, in Structure and Function of Biologically Active Peptides: Bradykinin, Kallidin and Congeners (Erdös EG ed) pp 91-107, The New York Academy of Sciences, New York.
36. Xu J, Carretero OA, Sun Y, Shesely EG, Rhaleb N-E, Liu Y-H, Liao T-D, Yang JJ, Bader M, and Yang X-P (2005) Role of the B1 kinin receptor in the regulation of cardiac function and remodeling after myocardial infarction. Hypertension 45:747-753.
37. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, and Dagenais G (2000) Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153.